HYBIO(SZ:300199) Zheng Quan Shi Bao Wang·2025-09-19 02:09Core Insights - The 10th Huawei Connect Conference was held in Shanghai from September 18 to 20, focusing on the future development trends and solutions in the pharmaceutical industry [1] - Hanyu Pharmaceutical, a leader in peptide drug research and production, launched a peptide AI process optimization assistant in collaboration with Huawei Cloud, marking a significant milestone in their partnership [1][2] Group 1: Collaboration and Technology - Hanyu Pharmaceutical and Huawei Cloud signed a comprehensive cooperation agreement on April 27, 2023, focusing on drug research model applications, digital platform construction, data governance, and AI talent cultivation [1] - The newly launched AI process optimization assistant utilizes over 100,000 historical process data accumulated by Hanyu Pharmaceutical, creating an intelligent private database that integrates with global authoritative chemical databases [2] Group 2: Performance Metrics - The AI process optimization assistant has demonstrated breakthrough results in various research and production stages, showcasing the significant application value of large model technology in pharmaceutical research [2] - Quantitative data indicates that the application of the large model will shorten research and development cycles by 45%, reduce trial and error costs by over 20%, enhance process parameter decision efficiency by 90%, and improve batch qualification rates by 22% [2] Group 3: Industry Alignment and Future Directions - The collaboration aligns with national policies promoting digital transformation in the pharmaceutical industry, as outlined in the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)" [3] - Hanyu Pharmaceutical's Vice President emphasized the importance of this collaboration as a practical example of the pharmaceutical industry embracing "new quality productivity" and plans to deepen cooperation while ensuring data security and compliance [3]